Good
Mostly Aligned
Patient Risk:
Low
Summary
Most safety-related boxed-warning and contraindication claims match the label. The only notable gap is slightly interpretive phrasing of the symptom counseling (“red-flag”/“warrant evaluation”) beyond a close restatement of labeled symptom-reporting guidance.
Category Scores
Accurate Statements
Trulicity (dulaglutide) is a GLP-1 receptor agonist.
11 DESCRIPTION: Dulaglutide is a human GLP-1 receptor agonist.
Trulicity carries a boxed warning for thyroid C-cell tumors based on findings in rodents.
WARNING: RISK OF THYROID C-CELL TUMORS: dose-related, treatment-duration-dependent increase in thyroid C-cell tumors in male and female rats.
Dulaglutide caused thyroid C-cell tumors in animal studies.
WARNING: RISK OF THYROID C-CELL TUMORS: dulaglutide causes thyroid C-cell tumors in male and female rats after lifetime exposure.
Human data have not established that Trulicity directly causes medullary thyroid cancer.
WARNING: RISK OF THYROID C-CELL TUMORS: 'It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans...'.
Trulicity should not be used in people with a personal or family history of medullary thyroid cancer (MTC).
4 CONTRAINDICATIONS and WARNING: 'TRULICITY is contraindicated in patients with a personal or family history of MTC...'.
Trulicity should not be used in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
4 CONTRAINDICATIONS and WARNING: '...in patients with MEN 2.'
In animal studies, dulaglutide increased the risk of thyroid C-cell tumors in rodents.
WARNING: RISK OF THYROID C-CELL TUMORS: dose-related and treatment-duration-dependent increase in incidence of thyroid C-cell tumors in rats.
Trulicity is contraindicated in people with a personal or family history of medullary thyroid cancer (MTC).
4 CONTRAINDICATIONS.
Trulicity is contraindicated in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
4 CONTRAINDICATIONS.
Unsupported Statements
The boxed warning for GLP-1 receptor agonists regarding “thyroid tumors” is primarily about medullary thyroid cancer (MTC), a cancer of thyroid C cells.
Partially supported by the label’s use of MTC as an example within 'thyroid C-cell tumors, including medullary thyroid carcinoma (MTC)' but the claim frames the warning as 'primarily about' MTC rather than faithfully restating the label’s broader 'thyroid C-cell tumors' wording.
Contradictions
Important Omissions
The label also states that routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with TRULICITY.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response accurately reflects the boxed-warning animal finding, the uncertainty for human causality, and the contraindications for personal/family history of MTC and MEN2. Minor interpretive and counseling-phrasing differences are unlikely to materially change safety meaning, though omission of the 'uncertain value' monitoring statement reduces label completeness.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Slightly interpretive framing ("primarily about MTC" and "red-flag"/"warrant evaluation") versus the label’s more specific phrasing about 'thyroid C-cell tumors' and advising patients to report symptoms to their physician.
Suggested Improvement
Rephrase to closely match the label: emphasize 'thyroid C-cell tumors, including MTC' and state that patients should report listed symptoms (e.g., lump in the neck, persistent hoarseness, dysphagia, dyspnea) to their physician; optionally include that routine calcitonin/thyroid ultrasound monitoring is of uncertain value.